中文版 | English

个人主页

关键词云

成果统计

合作作者[TOP 5]

  • 王诗翔

    合作成果数：18

  • 吴涛

    合作成果数：17

  • 何早柯

    合作成果数：12

  • 吴宸旭

    合作成果数：12

  • 赵翔宇

    合作成果数：11

访问统计


  总访问量
 2440
  访问来源
    内部： 45
    外部： 2395
    国内： 2200
    国外： 240

  年访问量
 202
  访问来源
    内部： 2
    外部： 200
    国内： 189
    国外： 13

  月访问量
 0
  访问来源
    内部： 0
    外部： 0
    国内： 0
    国外： 0

访问量

访问量

1. Seq2Neo: A Comprehensive Pipeline for Cancer Neoantigen Immunogeni.. [1266]
2. 一种肿瘤基因组拷贝数变异特征模式识别方法及其应用 [1158]
3. Extrachromosomal DNA formation enables tumor immune escape potenti.. [964]
4. LRF maintains genome integrity by regulating the non-homologous en.. [903]
5. Copy number signature analysis tool and its application in prostat.. [807]
6. Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and .. [785]
7. 一种简易高效的肿瘤免疫治疗生物标志物及其用途 [782]
8. Oncogenic EFNA4 Amplification Promotes Lung Adenocarcinoma Lymph N.. [758]
9. The repertoire of copy number alteration signatures in human cance.. [693]
10. Ggct (g-glutamyl cyclotransferase) plays an important role in eryt.. [692]
11. Accurate prediction of pan-cancer types using machine learning wit.. [675]
12. Association of CSMD1 with Tumor Mutation Burden and Other Clinical.. [630]
13. APOBEC3B and APOBEC mutational signature as potential predictive m.. [622]
14. Neodb: a comprehensive neoantigen database and discovery platform .. [605]
15. UCSCXenaShiny: An R/CRAN Package for Interactive Analysis of UCSC .. [599]
16. Addressing the Enzyme-independent tumor-promoting function of NAMP.. [575]
17. TLimmuno2: predicting MHC class II antigen immunogenicity through .. [474]
18. Sigflow: an automated and comprehensive pipeline for cancer genome.. [470]
19. Ras Downstream Effector GGCT Alleviates Oncogenic Stress [469]
20. 一种肿瘤新抗原特征分析与免疫原性预测工具及其应用 [443]
21. Somatic human ZBTB7A zinc finger mutations promote cancer progress.. [433]
22. Allosterically inhibited PFKL via prostaglandin E2 withholds gluco.. [431]
23. 肿瘤免疫：免疫系统与肿瘤细胞的持续战斗 [426]
24. Can tumor mutational burden determine the most effective treatment.. [413]
25. Antigen presentation and tumor immunogenicity in cancer immunother.. [410]
26. Quantification of neoantigen-mediated immunoediting in cancer evol.. [409]
27. 一种简洁全面的拷贝数变异模式识别方法及其应用 [395]
28. 一类适应低氧或缺氧微环境的肿瘤的治疗靶点及其应用 [384]
29. 一种肿瘤样本免疫编辑状态定量方法及其应用 [364]
30. CAR-Toner: an AI-driven approach for CAR tonic signaling predictio.. [357]
31. Copy number alteration features in pan-cancer homologous recombina.. [356]
32. c-Abl Kinase Targets Tight Junction Protein ZO-2 in Regulation of .. [349]
33. The predictive power of tumor mutational burden in lung cancer imm.. [336]
34. Hiplot: a comprehensive and easy-to-use web service for boosting p.. [300]
35. Seq2Neo: a comprehensive pipeline for cancer neoantigen im-munogen.. [294]
36. The UCSCXenaTools R package: a toolkit for accessing genomics data.. [292]
37. Quantification of Neoantigen-Mediated Immunoediting in Cancer Evol.. [290]
38. Pan-cancer noncoding genomic analysis identifies functional CDC20 .. [286]
39. 一种生物标志物组合及用于判断肿瘤原发部位的系统 [280]
40. 构建HRD预测模型的方法、HRD预测模型及CNA特征的应用 [256]
41. 一种肿瘤免疫生物标志物及其用途 [248]
42. 一种肿瘤免疫治疗的标志物 [242]
43. Essential role for Ggct in erythrocyte antioxidant defense [210]
44. TCfinder: Robust tumor cell discrimination in scRNA‐seq based on .. [165]
45. Pep2TCR: Accurate prediction of CD4 T cell receptor binding specif.. [41]

下载量

1. 一种肿瘤基因组拷贝数变异特征模式识别方法及其应用 [418]
2. Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and .. [304]
3. 一种简易高效的肿瘤免疫治疗生物标志物及其用途 [294]
4. LRF maintains genome integrity by regulating the non-homologous en.. [288]
5. Association of CSMD1 with Tumor Mutation Burden and Other Clinical.. [263]
6. Extrachromosomal DNA formation enables tumor immune escape potenti.. [248]
7. Copy number signature analysis tool and its application in prostat.. [243]
8. Oncogenic EFNA4 Amplification Promotes Lung Adenocarcinoma Lymph N.. [240]
9. The repertoire of copy number alteration signatures in human cance.. [203]
10. Seq2Neo: A Comprehensive Pipeline for Cancer Neoantigen Immunogeni.. [197]
11. Neodb: a comprehensive neoantigen database and discovery platform .. [114]
12. Essential role for Ggct in erythrocyte antioxidant defense [49]
13. c-Abl Kinase Targets Tight Junction Protein ZO-2 in Regulation of .. [38]
14. Seq2Neo: a comprehensive pipeline for cancer neoantigen im-munogen.. [31]
15. Addressing the Enzyme-independent tumor-promoting function of NAMP.. [24]
16. UCSCXenaShiny: An R/CRAN Package for Interactive Analysis of UCSC .. [18]
17. Ggct (g-glutamyl cyclotransferase) plays an important role in eryt.. [15]
18. Antigen presentation and tumor immunogenicity in cancer immunother.. [14]
19. Can tumor mutational burden determine the most effective treatment.. [14]
20. Allosterically inhibited PFKL via prostaglandin E2 withholds gluco.. [14]
21. The predictive power of tumor mutational burden in lung cancer imm.. [13]
22. Ras Downstream Effector GGCT Alleviates Oncogenic Stress [11]
23. The UCSCXenaTools R package: a toolkit for accessing genomics data.. [11]
24. Sigflow: an automated and comprehensive pipeline for cancer genome.. [11]
25. 一种简洁全面的拷贝数变异模式识别方法及其应用 [11]
26. TCfinder: Robust tumor cell discrimination in scRNA‐seq based on .. [10]
27. Accurate prediction of pan-cancer types using machine learning wit.. [8]
28. Quantification of neoantigen-mediated immunoediting in cancer evol.. [5]
29. TLimmuno2: predicting MHC class II antigen immunogenicity through .. [5]
30. CAR-Toner: an AI-driven approach for CAR tonic signaling predictio.. [5]
31. APOBEC3B and APOBEC mutational signature as potential predictive m.. [4]
32. Hiplot: a comprehensive and easy-to-use web service for boosting p.. [3]
33. Copy number alteration features in pan-cancer homologous recombina.. [3]
34. 一种生物标志物组合及用于判断肿瘤原发部位的系统 [3]
35. 构建HRD预测模型的方法、HRD预测模型及CNA特征的应用 [3]
36. 一种肿瘤免疫生物标志物及其用途 [2]
37. 肿瘤免疫：免疫系统与肿瘤细胞的持续战斗 [2]
38. Quantification of Neoantigen-Mediated Immunoediting in Cancer Evol.. [2]
39. Pep2TCR: Accurate prediction of CD4 T cell receptor binding specif.. [2]
40. Somatic human ZBTB7A zinc finger mutations promote cancer progress.. [1]
41. 一类适应低氧或缺氧微环境的肿瘤的治疗靶点及其应用 [1]